KEYNOTE-585

Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer

Yung Jue Bang, Eric Van Cutsem, Charles S. Fuchs, Atsushi Ohtsu, Josep Tabernero, David H. Ilson, WooJin Hyung, Vivian E. Strong, Thorsten Oliver Goetze, Takaki Yoshikawa, Laura H. Tang, Peggy May Tan Hwang, Nancy Webb, David Adelberg, Kohei Shitara

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Surgical resection is the only curative treatment option for gastric cancer. Despite widespread adoption of multimodality perioperative treatment strategies, 5-year overall survival rates remain low. In patients with advanced gastric or gastroesophageal junction adenocarcinoma, pembrolizumab has demonstrated promising efficacy and manageable safety as monotherapy in previously treated patients and as first-line therapy in combination with cisplatin and 5-fluorouracil. Combining chemotherapy with pembrolizumab in the neoadjuvant/adjuvant setting may benefit patients with locally advanced, resectable disease. Aim: To describe the design and rationale for the global, multicenter, randomized, double-blind, Phase III KEYNOTE-585 study to evaluate the efficacy and safety of pembrolizumab plus chemotherapy compared with placebo plus chemotherapy as neoadjuvant/adjuvant treatment for localized gastric or gastroesophageal junction adenocarcinoma. ClinicalTrials.gov: NCT0322142.

Original languageEnglish
Pages (from-to)943-952
Number of pages10
JournalFuture Oncology
Volume15
Issue number9
DOIs
Publication statusPublished - 2019 Mar 1

Fingerprint

Stomach Neoplasms
Esophagogastric Junction
Drug Therapy
Stomach
Adenocarcinoma
Safety
Neoadjuvant Therapy
Fluorouracil
Cisplatin
Therapeutics
Survival Rate
Placebos
pembrolizumab

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Bang, Y. J., Van Cutsem, E., Fuchs, C. S., Ohtsu, A., Tabernero, J., Ilson, D. H., ... Shitara, K. (2019). KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncology, 15(9), 943-952. https://doi.org/10.2217/fon-2018-0581
Bang, Yung Jue ; Van Cutsem, Eric ; Fuchs, Charles S. ; Ohtsu, Atsushi ; Tabernero, Josep ; Ilson, David H. ; Hyung, WooJin ; Strong, Vivian E. ; Goetze, Thorsten Oliver ; Yoshikawa, Takaki ; Tang, Laura H. ; Hwang, Peggy May Tan ; Webb, Nancy ; Adelberg, David ; Shitara, Kohei. / KEYNOTE-585 : Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. In: Future Oncology. 2019 ; Vol. 15, No. 9. pp. 943-952.
@article{e46e08f4e08d49d2b5a1dc75629706c7,
title = "KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer",
abstract = "Background: Surgical resection is the only curative treatment option for gastric cancer. Despite widespread adoption of multimodality perioperative treatment strategies, 5-year overall survival rates remain low. In patients with advanced gastric or gastroesophageal junction adenocarcinoma, pembrolizumab has demonstrated promising efficacy and manageable safety as monotherapy in previously treated patients and as first-line therapy in combination with cisplatin and 5-fluorouracil. Combining chemotherapy with pembrolizumab in the neoadjuvant/adjuvant setting may benefit patients with locally advanced, resectable disease. Aim: To describe the design and rationale for the global, multicenter, randomized, double-blind, Phase III KEYNOTE-585 study to evaluate the efficacy and safety of pembrolizumab plus chemotherapy compared with placebo plus chemotherapy as neoadjuvant/adjuvant treatment for localized gastric or gastroesophageal junction adenocarcinoma. ClinicalTrials.gov: NCT0322142.",
author = "Bang, {Yung Jue} and {Van Cutsem}, Eric and Fuchs, {Charles S.} and Atsushi Ohtsu and Josep Tabernero and Ilson, {David H.} and WooJin Hyung and Strong, {Vivian E.} and Goetze, {Thorsten Oliver} and Takaki Yoshikawa and Tang, {Laura H.} and Hwang, {Peggy May Tan} and Nancy Webb and David Adelberg and Kohei Shitara",
year = "2019",
month = "3",
day = "1",
doi = "10.2217/fon-2018-0581",
language = "English",
volume = "15",
pages = "943--952",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "9",

}

Bang, YJ, Van Cutsem, E, Fuchs, CS, Ohtsu, A, Tabernero, J, Ilson, DH, Hyung, W, Strong, VE, Goetze, TO, Yoshikawa, T, Tang, LH, Hwang, PMT, Webb, N, Adelberg, D & Shitara, K 2019, 'KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer', Future Oncology, vol. 15, no. 9, pp. 943-952. https://doi.org/10.2217/fon-2018-0581

KEYNOTE-585 : Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. / Bang, Yung Jue; Van Cutsem, Eric; Fuchs, Charles S.; Ohtsu, Atsushi; Tabernero, Josep; Ilson, David H.; Hyung, WooJin; Strong, Vivian E.; Goetze, Thorsten Oliver; Yoshikawa, Takaki; Tang, Laura H.; Hwang, Peggy May Tan; Webb, Nancy; Adelberg, David; Shitara, Kohei.

In: Future Oncology, Vol. 15, No. 9, 01.03.2019, p. 943-952.

Research output: Contribution to journalArticle

TY - JOUR

T1 - KEYNOTE-585

T2 - Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer

AU - Bang, Yung Jue

AU - Van Cutsem, Eric

AU - Fuchs, Charles S.

AU - Ohtsu, Atsushi

AU - Tabernero, Josep

AU - Ilson, David H.

AU - Hyung, WooJin

AU - Strong, Vivian E.

AU - Goetze, Thorsten Oliver

AU - Yoshikawa, Takaki

AU - Tang, Laura H.

AU - Hwang, Peggy May Tan

AU - Webb, Nancy

AU - Adelberg, David

AU - Shitara, Kohei

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background: Surgical resection is the only curative treatment option for gastric cancer. Despite widespread adoption of multimodality perioperative treatment strategies, 5-year overall survival rates remain low. In patients with advanced gastric or gastroesophageal junction adenocarcinoma, pembrolizumab has demonstrated promising efficacy and manageable safety as monotherapy in previously treated patients and as first-line therapy in combination with cisplatin and 5-fluorouracil. Combining chemotherapy with pembrolizumab in the neoadjuvant/adjuvant setting may benefit patients with locally advanced, resectable disease. Aim: To describe the design and rationale for the global, multicenter, randomized, double-blind, Phase III KEYNOTE-585 study to evaluate the efficacy and safety of pembrolizumab plus chemotherapy compared with placebo plus chemotherapy as neoadjuvant/adjuvant treatment for localized gastric or gastroesophageal junction adenocarcinoma. ClinicalTrials.gov: NCT0322142.

AB - Background: Surgical resection is the only curative treatment option for gastric cancer. Despite widespread adoption of multimodality perioperative treatment strategies, 5-year overall survival rates remain low. In patients with advanced gastric or gastroesophageal junction adenocarcinoma, pembrolizumab has demonstrated promising efficacy and manageable safety as monotherapy in previously treated patients and as first-line therapy in combination with cisplatin and 5-fluorouracil. Combining chemotherapy with pembrolizumab in the neoadjuvant/adjuvant setting may benefit patients with locally advanced, resectable disease. Aim: To describe the design and rationale for the global, multicenter, randomized, double-blind, Phase III KEYNOTE-585 study to evaluate the efficacy and safety of pembrolizumab plus chemotherapy compared with placebo plus chemotherapy as neoadjuvant/adjuvant treatment for localized gastric or gastroesophageal junction adenocarcinoma. ClinicalTrials.gov: NCT0322142.

UR - http://www.scopus.com/inward/record.url?scp=85063237152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063237152&partnerID=8YFLogxK

U2 - 10.2217/fon-2018-0581

DO - 10.2217/fon-2018-0581

M3 - Article

VL - 15

SP - 943

EP - 952

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 9

ER -